Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer molecular libraries

MedKoo product information:

CNDO101

CNDO101 is the 4th Generation Anthracycline agent. Anthracyclines such as doxorubicin are used to treat many hematologic and epithelial cancers. Anthracyclines work by inhibiting topoisomerase II, a DNA-protein complex. Doxorubicin is one of the most widely used chemotherapy drugs due to its success in treating breast cancer, non-Hodgkins lymphoma (NHL), multiple myeloma, and pediatric acute lymphoblastic leukemia.

However, anthracyclines in general have been associated with dose related cardiotoxicity. This safety concern and the need to limit a patient’s exposure to doxorubicin have limited the ability of oncologists to utilize these powerful agents to their patients’ benefits.

CNDO101, Coronado Bioscience’s next-generation anthracycline therapy, is designed to improve the safety of anthracycline use without compromising efficacy. Doxorubicin cardiotoxicity—a critical, dose-limiting complication of therapy—appears to be caused by two structural elements that are common to the anthracycline molecule: the C5 quinone and the C13 carbonyl.

CNDO101 has been rationally designed to remove these two structural elements. The new compound, 5-imino-13-deoxydoxorubicin, appears to eliminate toxicity while maintaining the positive benefits of anthracyclines.

Nonclinical studies of CNDO101 have demonstrated that the product showed no cardiotoxicity (in a chronic rabbit model) yet retained potent antitumor activity in vitro and in animals. Theoretically, CNDO101 may easily complement existing chemotherapy options as an addition to established treatment protocols or by expanding the use of an anthracycline to tumors where use is limited by cardiotoxicity. See Coronado Biosciences's website.

Current developer: Coronado Biosciences, Inc.